Óscar Alberto Pérez-González

Dr. Óscar Alberto Pérez-González

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2013 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA
VVVanessa Villegas-Ruíz
Vanessa Villegas-Ruíz
ÓPÓscar Alberto Pérez-González
Óscar Alberto Pérez-González
MSMauricio Salcedo
Mauricio Salcedo
JMJosé Moreno
José Moreno
Background: Studies of alternative mRNA splicing (AS) in health and disease have yet to yield the complete picture of protein diversity and its role in physiology and pathology. Some forms of cancer appear to be associated to certain alternative mRNA splice variants, but their role in the cancer development and outcome is unclear.Methods: We examined AS profiles by means of whole genome exon expression microarrays (Affymetrix GeneChip 1.0) in ovarian tumors and ovarian cancer-derived cell lines, compared to healthy ovarian tissue. Alternatively spliced genes expressed predominantly in ovarian tumors and cell lines were confirmed by RT-PCR.Results: Among several significantly overexpressed AS genes in malignant ovarian tumors and ovarian cancer cell lines, the most significant one was that of the zinc finger protein ZNF695, with two previously unknown mRNA splice variants identified in ovarian tumors and cell lines. The identity of ZNF695 AS variants was confirmed by cloning and sequencing of the amplicons obtained from ovarian cancer tissue and cell lines.Conclusions: Alternative ZNF695 mRNA splicing could be a marker of ovarian cancer with possible implications on its pathogenesis.

Verified
Journal Article
Open access
PDF file
ARAngélica Rangel-López
Angélica Rangel-López
MMMINERVA MATA
MINERVA MATA
ÓPÓscar Alberto Pérez-González
Óscar Alberto Pérez-González
RLRicardo Lopez-Romero
Ricardo Lopez-Romero
DLDulce López-Sánchez
Dulce López-Sánchez
JAJosé Arellano-Galindo
José Arellano-Galindo
Patients with end-stage renal disease (ESRD) are at increased risk of cardiovascular disease (CVD), such as myocardial infarction (MI). Uremic toxins and endothelial dysfunction are central to this process. In this exploratory study, we used the Affymetrix GeneChip microarray to investigate the gene expression profile in uremic serum-induced human coronary arterial endothelial cells (HCAECs) from ESRD patients with and without MI (UWI and UWOI groups) as an approach to its underlying mechanism. We also explored which pathways are involved in this process. We found 100 differentially expressed genes (DEGs) among the conditions of interest by supervised principal component analysis and hierarchical cluster analysis. The expressions of four major DEGs were validated by quantitative RT-PCR. Pathway analysis and molecular network were used to analyze the interaction and expression patterns. Ten pathways were identified as the main enriched metabolic pathways according to the transcriptome profiling analysis, which were, among others, positive regulation of inflammatory response, positive regulation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) cascade, cardiac muscle cell development, highlighting positive regulation of mitogen-activated protein kinase (MAPK) activity (p = 0.00016). Up- and down-regulation of genes from HCAECs exposed to uremic serum could contribute to increased endothelial dysfunction and CVD in ESRD patients. Our study suggests that inflammation and the ERK-MAPK pathway are highly enriched in kidney disease patients with MI, suggesting their role in ESRD pathology. Further studies and approaches based on MAPK pathway interfering strategies are needed to confirm these data.

Verified
Journal Article
Open access
PDF file
RBRehotbevely Rehotbevely Barrientos-Ríos
Rehotbevely Rehotbevely Barrientos-Ríos
RRRodolfo Rodríguez-Jurado
Rodolfo Rodríguez-Jurado
LTLuz-María Torres-Espíndola
Luz-María Torres-Espíndola
MOMarimar M. Saez De Ocariz-Gutierrez
Marimar M. Saez De Ocariz-Gutierrez
JVJose Antonio Velázquez-Aragón
Jose Antonio Velázquez-Aragón
RVRafael Velazquez-Cruz
Rafael Velazquez-Cruz
Pilomatricoma is a rare benign cutaneous neoplasm that may occur more frequently in syndromic conditions such as Turner syndrome (TS). This study aimed to evaluate the prevalence and clinical characteristics of pilomatricoma and its association with clinical factors, serum vitamin D (VD) levels, and genetic variants in the VD pathway in patients with TS. Clinical variables and serum VD levels were obtained from medical records, and single-nucleotide variants in the GC, NADSYN1, and VDR genes were analyzed by allelic discrimination using real-time polymerase chain reaction. Among 97 patients with TS, six cases of histopathologically confirmed pilomatricoma were identified, corresponding to a prevalence of 6.2%, with lesions predominantly located on the head and upper extremities. Four patients (66.7%) had renal malformations. In exploratory multivariable analysis, renal malformations were significantly associated with pilomatricoma (adjusted OR = 14.2; 95% CI: 2.1–95.4; nominal p = 0.008; FDR-adjusted p = 0.032). No significant associations were observed with serum VD levels or the analyzed genetic variants. These findings suggest that pilomatricoma may be more frequent in TS than previously reported and identify an exploratory association between pilomatricoma and renal malformations. Given the small number of pilomatricoma cases, this association requires confirmation in larger independent cohorts.